SG Americas Securities LLC Has $1.95 Million Stake in Nevro Corp. (NYSE:NVRO)

SG Americas Securities LLC decreased its position in Nevro Corp. (NYSE:NVROGet Rating) by 16.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 26,934 shares of the medical equipment provider’s stock after selling 5,475 shares during the period. SG Americas Securities LLC’s holdings in Nevro were worth $1,948,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital Research Global Investors grew its holdings in Nevro by 15.6% during the fourth quarter. Capital Research Global Investors now owns 1,582,704 shares of the medical equipment provider’s stock worth $128,310,000 after purchasing an additional 213,670 shares during the period. Geode Capital Management LLC raised its position in shares of Nevro by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 571,954 shares of the medical equipment provider’s stock valued at $46,368,000 after buying an additional 10,053 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Nevro by 42.4% in the fourth quarter. Brown Advisory Inc. now owns 524,112 shares of the medical equipment provider’s stock valued at $42,489,000 after buying an additional 156,109 shares in the last quarter. Sei Investments Co. raised its position in Nevro by 5.5% during the fourth quarter. Sei Investments Co. now owns 456,822 shares of the medical equipment provider’s stock valued at $37,032,000 after purchasing an additional 23,919 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Nevro by 74.5% during the fourth quarter. Principal Financial Group Inc. now owns 434,320 shares of the medical equipment provider’s stock valued at $35,210,000 after purchasing an additional 185,461 shares in the last quarter.

Insider Buying and Selling at Nevro

In other news, General Counsel Kashif Rashid purchased 2,250 shares of the company’s stock in a transaction on Monday, May 9th. The stock was acquired at an average cost of $44.50 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the general counsel now directly owns 53,526 shares in the company, valued at approximately $2,381,907. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NVRO shares. JMP Securities lowered their price target on shares of Nevro from $125.00 to $95.00 and set a “market outperform” rating for the company in a report on Thursday, May 26th. Morgan Stanley cut their price target on shares of Nevro from $74.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Tuesday, June 7th. StockNews.com raised shares of Nevro from a “sell” rating to a “hold” rating in a research report on Thursday, July 21st. Truist Financial cut their price objective on shares of Nevro to $45.00 in a research report on Friday. Finally, Citigroup lowered their target price on shares of Nevro from $78.00 to $68.00 in a report on Tuesday, May 17th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $77.00.

Nevro Trading Down 1.3 %

NYSE:NVRO opened at $43.60 on Tuesday. Nevro Corp. has a one year low of $39.41 and a one year high of $157.87. The company has a debt-to-equity ratio of 0.77, a current ratio of 6.97 and a quick ratio of 5.68. The company’s 50-day simple moving average is $44.83 and its 200 day simple moving average is $60.58. The firm has a market capitalization of $1.54 billion, a P/E ratio of -11.18 and a beta of 1.03.

Nevro (NYSE:NVROGet Rating) last issued its earnings results on Wednesday, May 4th. The medical equipment provider reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.13. Nevro had a negative net margin of 35.25% and a negative return on equity of 38.02%. The firm had revenue of $87.40 million for the quarter, compared to the consensus estimate of $86.19 million. During the same quarter in the prior year, the firm posted ($0.85) earnings per share. The business’s revenue was down 1.4% on a year-over-year basis. As a group, analysts forecast that Nevro Corp. will post -2.9 EPS for the current fiscal year.

Nevro Company Profile

(Get Rating)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.

Read More

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVROGet Rating).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.